2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

602. Myeloid Oncogenesis: Basic: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Gene Therapy, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3201 RBM15::MKL1 maintains WTAP recruitment and blocks megakaryocytic differentiation independent of the RBM15 SPOC domain

Amos Espinosa, BA, MPhil, Madeline Mayday2, Mi Chen, PhD3, Lin Wang, MS4, Ping-Xia Zhang, MD, PhD5, Diane Krause, MD, PhD6
1 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States
2 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States
3 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States
4 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States
5 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States
6 Yale Stem Cell Center, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States, Yale University, School of Medicine, New Haven, Connecticut, United States

Background: Acute megakaryoblastic leukemia (AMKL) is an aggressive subtype of acute myeloid leukemia (AML) characterized by uncontrolled proliferation of megakaryoblasts that fail to differentiate. The recurrent t(1;22) translocation in infantile AMKL encodes the RBM15::MKL1 (RM) fusion protein that retains all functional domains of both RBM15, a regulator of N6-methyladenosine (m6A) RNA modification, and MKL1, a transcriptional coactivator. In order to understand how the RM fusion protein promotes leukemia, we previously showed that RM binds RNA with some target RNAs shared with RBM15 and some that are unique. RNAs uniquely bound to RM have elevated m6A levels and increased transcript stability. Here, we performed structure-function studies to determine the domains of RM that associated with the m6A methyltransferase complex (MTC) and their effects on RM-mediated block in megakaryocyte (Mk) maturation, with the long-term goal of defining therapeutically targetable domains of RM. We initially focused on the SPOC domain of RBM15 because it is known to interact with WTAP, a core component of the MTC.

Methods: We used two cellular models, the RM-expressing 6133 murine AMKL cell line derived from a knock-in mouse with human MKL1 knocked in downstream of endogenous murine Rbm15 and human erythroleukemia (HEL) cells engineered to have doxycycline (dox)-inducible expression of wildtype or mutant RM. HEL cells can be induced to undergo Mk like maturation with TPA. Co-immunoprecipitation (co-IP) assays, alanine scanning mutagenesis, structural modeling using AlphaFold3, and immunoblotting were used to define the molecular determinants of WTAP binding. For analysis of Mk maturation after disruption of the RBM15 SPOC domain in RM, conventional and intracellular flow cytometry as well as Wright-Giemsa-stained cells were used.

Results: We first demonstrated that RM is essential for the proliferation and survival of 6133 cells and inhibits Mk-like differentiation of TPA-treated HEL cells. The mean fluorescence intensity of TPA-induced CD49b decreased by 80-100% when RM expression was induced (p<0.05, n=3). To define the WTAP-binding interface, co-IP studies were performed using transient transfections of a vector encoding a FLAG-tagged RBM15 SPOC domain. Based on published data (Appel et al., Nat. Comm., 2023) and AlphaFold3 structural predictions, we tested the effects of alanine-scanning mutagenesis of two conserved basic patches in the RBM15 SPOC domain, which revealed that mutation of three residues in a highly conserved basic Patch (called Patch 1), but not residues within a moderately conserved basic Patch 2, abrogated WTAP binding (p<0.05 based on densitometry of co-IP blots, n=3).

Unexpectedly, these same mutations in the SPOC domain did not abrogate WTAP binding in the context of either full-length RBM15 or the RM fusion protein. Specifically, individual Patch 1 mutants, a triple Patch 1 mutant, and complete SPOC domain deletion all retained interaction with WTAP. Consistent with these protein-protein interaction findings, HEL cells expressing SPOC-mutant or SPOC-deleted RM remained fully capable of blocking TPA-induced megakaryocytic maturation, based on lack of induction of CD49b expression at 24 hrs as well as a block in polyploidization with maintenance of an immature morphology comparable to unmutated RM.

Conclusions: These findings identify a conserved WTAP-binding interface within the RBM15 SPOC domain in isolation. But, we also demonstrate that this interaction is dispensable in the context of the full-length RM fusion protein. Instead, RM can bind the m6A MTC through alternative SPOC-independent mechanism that preserves WTAP association and maintains the leukemic differentiation block. These surprising results suggest that targeting the canonical SPOC-WTAP interaction is unlikely to disrupt RM-driven leukemogenesis, and that further work is needed to identify the RM domains that mediate m6A MTC association.

Limitations and Future Directions: Because SPOC domain disruption does not abolish WTAP binding, we are testing whether the combined deletion of the RNA-recognition motif 1 (RRM1) and the SPOC domain disrupts WTAP association. We are also using EpiPlex (from AlidaBio) to determine whether SPOC-domain disruption alters global or transcript-specific m6A deposition despite retained WTAP binding, thereby defining epitranscriptomic consequences of this alternative recruitment mechanism.
Amos Espinosa, BA, MPhil: No relevant conflicts of interest to declare.